COVID-19

SARS-CoV-2 Viral Load on Admission Is Associated With 30-Day Mortality | Cognitive deficits in people who have recovered from COVID-19 relative to controls: An N=84,285 online study | Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

Reports of “Long-COVID”, are rising: Attributes and predictors of “Long COVID” | Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity | More people are getting COVID-19 twice, suggesting immunity wanes quickly in some | Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19 | ApoE isoform-dependent SARS-CoV-2 neurotropism and cellular response

A distinct innate immune signature marks progression from mild to severe COVID-19 | Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19 | Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection

Veterans Health Administration COVID-19 (VACO) Index for COVID-19 Mortality | V-safe After Vaccination Health Checker | COVID-19 Vaccines and Severe Allergic Reactions | FDA Issues Emergency Use Authorization for Second COVID-19 Vaccine | K reports new variant, termed VUI 202012/01

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK | FDA issues Emergency Use Authorization for first COVID-19 vaccine

Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19 | The Advisory Committee on Immunization Practices’ Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020 | Updated CDC guidance on when to quarantine

AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19 | Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results | Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19 | A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

Immunological memory to SARS-CoV-2 assessed for greater than six months after infection | Sixty-Day Outcomes Among Patients Hospitalized With COVID-19 | Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany | FDA Authorizes First COVID-19 Test for Self-Testing at Home

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans | Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from phase 3 study | FDA Authorizes Monoclonal Antibody for Treatment of COVID-19

Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology | SARS-CoV-2 direct cardiac damage through spike-mediated cardiomyocyte 3 fusion | Prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised cancer patient.